VRDN | Ticker Profile - Titan Protect

VRDN

Viridian Therapeutics, Inc.

Healthcare · Biotechnology · NCM

$15.78

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.87

Based on estimated future earnings — lower means cheaper

Rev Growth

+95.8%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-58.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$34.50

+119% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 16 analysts covering this stock

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.

https://www.viridiantherapeutics.com

Country: United States Employees: 252 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.621

Good returns relative to risk taken

Kelly Fraction

0.0526

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.344

Drawdown risk outweighs the returns — higher risk profile

Annual Return

20.8%

Historical annualised return based on price data

Max Drawdown

-60.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.82

Less volatile than the market — more defensive

52W High

$34.29

54% below the year high

52W Low

$13.18

20% above the year low

Avg Volume

2,840,929

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.5

Days it would take all short sellers to cover — higher means more crowded

Short % Float

13.4%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-3.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

8.39

Heavy leverage — higher financial risk if revenues decline

Current Ratio

15.15

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

14.71

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-82,389.4%

Profit from core operations before interest and tax

Free Cash Flow

$-182,550,752

Negative — the business is spending more than it generates

Revenue (TTM)

$71M

Total revenue over the last 12 months

Net Income

$-303,267,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$50.00

Target Median

$34.50

Target Low

$20.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go